home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9605a.zip
/
M9650424.TXT
< prev
next >
Wrap
Text File
|
1996-03-09
|
3KB
|
40 lines
Document 0424
DOCN M9650424
TI Further clinical studies of curdlan sulfate (CRDS)--an anti-HIV agent.
DT 9605
AU Gordon M; Guralnik M; Kaneko Y; Mimura T; Goodgame J; Lang W; Aji Pharma
USA, Inc., Glenpointe Centre West, Teaneck, NJ 07666,; USA.
SO J Med. 1995;26(3-4):97-131. Unique Identifier : AIDSLINE MED/96098544
AB Curdlan sulfate (CRDS) is a semi-synthetic sulfated polysaccharide which
inhibits the attachment of HIV to T-cells, and also has intracellular
anti-HIV activity. In Phase I clinical trials, CRDS was found in 4 hr
i.v. infusions, to be well tolerated up to 200 mg/70 kg and unexpectedly
to produce marked, dose-related increases in CD4 lymphocytes in
HIV-infected patients. Prolongation of bleeding time is expected to be
the dose limiting toxicity, but no episodes of bleeding were seen. In
one of the studies in this report, CRDS was administered i.v. daily for
7 days to HIV patients at doses of 40, 100, 140 and 180 mg/70 kg/day. At
the higher doses, marked increases in CD4 and CD8 lymphocytes were
observed. These increases mainly returned to baseline after 24 hr. To
further delineate the pharmacokinetics of these changes in CD4 and CD8
lymphocytes, another Phase I study was done in which CRDS was infused
i.v. over a 30 min period in HIV patients at single doses of 25, 50, 75,
100, 125, 150, 175 and 200 mg/70 kg/day. The drug was well tolerated in
all cases and marked increases in CD4 lymphocytes were again seen at the
higher doses, in some cases amounting to increases of 500 cells/mm3
after a single dose. The half-life of CRDS in man was found to be about
two hours, as measured by activated partial thromboplastin time (APTT)
and by plasma assays.
DE Antiviral Agents/ADMINISTRATION & DOSAGE/PHARMACOKINETICS/ *THERAPEUTIC
USE Chromatography, Gel CD4 Lymphocyte Count/*DRUG EFFECTS
CD4-Positive T-Lymphocytes/DRUG EFFECTS CD8-Positive
T-Lymphocytes/*DRUG EFFECTS Glucans/ADMINISTRATION &
DOSAGE/PHARMACOKINETICS/*THERAPEUTIC USE Human HIV Infections/*DRUG
THERAPY/IMMUNOLOGY Lymphocyte Count/DRUG EFFECTS Partial
Thromboplastin Time CLINICAL TRIAL CLINICAL TRIAL, PHASE I JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).